Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • News

Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting

By Benzinga Newsdesk
June 18, 8:06 AM
Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDPADVANCE Clinical Program Reflects Takeda's

TAK

Read More
2 minute read
  • Biotech
  • Equities
  • FDA
  • General
  • Health Care
  • Large Cap
  • Media
  • News

FDA Approves Merck’s Pneumococcal Vaccine As First Shot Designed For Adults

By Vandana Singh
June 18, 8:05 AM
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced endometrial carcinoma.

MRK

Read More
1 minute read
  • Biotech
  • General
  • News

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma

By Benzinga Newsdesk
June 18, 8:05 AM
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to dateFavorable mOS and mPFS demonstrated in pooled

ERAS

Read More
2 minute read
  • ETFs
  • Exclusives
  • Interview
  • Specialty ETFs
  • Tech
  • Top Stories

EXCLUSIVE: Meta’s AI, Metaverse Growth Drive Launch Of New Direxion Leveraged And Inverse ETFs

By Surbhi Jain
June 18, 8:02 AM
New ETFs from Direxion, METU and METD, provide traders with tools to capitalize on short-term movements of Meta Platforms Inc (NASDAQ:META) stock.

META

Read More
3 minute read
  • Analyst Ratings

Navigating 8 Analyst Ratings For Paylocity Holding

By Benzinga Insights
June 18, 8:01 AM
Across the recent three months, 8 analysts have shared their insights on Paylocity Holding (NASDAQ:PCTY), expressing a variety…

PCTY

Read More
3 minute read
  • Analyst Ratings

Analyst Ratings For CRH

By Benzinga Insights
June 18, 8:01 AM
6 analysts have expressed a variety of opinions on CRH (NYSE:CRH) over the past quarter, offering a diverse…

CRH

Read More
4 minute read
  • Analyst Ratings

Beyond The Numbers: 11 Analysts Discuss Dynatrace Stock

By Benzinga Insights
June 18, 8:01 AM
During the last three months, 11 analysts shared their evaluations of Dynatrace (NYSE:DT), revealing diverse outlooks from bullish…

DT

Read More
3 minute read
  • Analyst Ratings

Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews

By Benzinga Insights
June 18, 8:00 AM
Throughout the last three months, 7 analysts have evaluated Praxis Precision Medicine (NASDAQ:PRAX), offering a diverse set of…

PRAX

Read More
3 minute read
  • Analyst Ratings

Unveiling 4 Analyst Insights On DigitalBridge Gr

By Benzinga Insights
June 18, 8:00 AM
DigitalBridge Gr (NYSE:DBRG) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from…

DBRG

Read More
4 minute read
  • Analyst Ratings

Analyst Ratings For Micron Technology

By Benzinga Insights
June 18, 8:00 AM
Micron Technology (NASDAQ:MU) has been analyzed by 30 analysts in the last three months, revealing a diverse range…

MU

Posts pagination

Previous 1 … 67 68 69 … 19,074 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service